Introduction like p53, where regulation of activity appears to be primarily at the level of protein abundance, the growthThe development of human cancers is frequently associsuppressive function of pRB is primarily regulated by ated with the inactivation of two major tumor supprescell cycle-dependent phosphorylations (Weinberg, 1995) . sion pathways represented by the retinoblastoma proFollowing mitosis, pRB emerges in a hypophosphorytein, pRB, and by p53 (Weinberg, 1995; Sherr, 1996;  lated form, which becomes hyperphosphorylated during Levine, 1997) . Via distinct mechanisms, pRB and p53 mid to late G1 phase and then maintains this hyperphosplay critical roles in transducing a variety of growth inphorylated state throughout the remainder of the cell hibitory signals to the cell cycle control machinery, and cycle. Hypophosphorylated pRB binds and controls a their inactivation may lead to uncontrolled cell proliferanumber of cellular transcription factors such as the tion and a predisposition to neoplasia. pRB exerts most, members of the E2F family, while hyperphosphorylated if not all, of its growth suppressive effects in the first pRB no longer interacts with these proteins. The kinases two-thirds of the G1 phase of the cell cycle by binding that have been strongly implicated as responsible for transcription factors required for initiating and propRB phosphorylation are the cyclin-dependent kinases gressing through S phase. When bound by pRB, these (CDKs), particularly the cyclin D-dependent kinases transcription factors are converted from transcriptional CDK4 and CDK6 (Ewen et al., 1993; Kato et al., 1993) . activators to transcriptional repressors, thereby pre-
The activity of CDK4/6 is inhibited by association with venting cells from exiting the G1 phase of the cell cycle CDK inhibitors (Sherr and Roberts, 1995) . A specific (Weinberg, 1995) . On the other hand, p53 is itself a traninhibitor of CDK4/6, p16INK4a, is mutated, deleted, or scription factor that activates the expression of genes down-regulated by promoter methylation in many huthat induce a G1 cell cycle arrest or apoptosis in reman tumors. In human cancers, the estimated frequency sponse to DNA damage (Gottlieb and Oren, 1996 ; Ko of genetic alteration involving the p16 locus is believed and Prives, 1996, Levine, 1997) . The concurrent inactivato be second only to alteration of p53 (Hunter and Pines, tion of these two pathways in human cancer occurs 1994; Sherr, 1996) . The extraordinarily high frequency frequently and argues that unscheduled entry into the of genetic alteration of the INK4a locus in human cancer may stem from its unique genomic organization. In addition to INK4a (Serrano et al., 1993) , this locus encodes
To whom correspondence should be addressed. # These authors contributed equally to this work. a second protein, ARF, whose enforced expression, like that of INK4a, also induces cell cycle arrest and whose disruption in mice results in development of multiple tumor types early in life (Quelle et al., 1995; Kamijo et al., 1997) . The ARF-INK4a locus contains two unique first exons, designated 1␣ and 1␤, which are spliced into common exons 2 and 3 (Duro et al., 1995; Mao et al., 1995; Quelle et al., 1995; Stone et al., 1995) . While the exon 1␣-exon 2-exon 3 transcript encodes the CDK4/6-specific inhibitor INK4a, the exon 1␤-exon 2-exon 3 transcript through an alternative reading frame encodes ARF, which bears no homology to INK4a at the amino acid level (Quelle et al., 1995) . As such, homozygous deletion of the locus, which occurs frequently in a variety of human cancers, causes a loss of both the INK4a gene and the ARF gene, spawning complications in determining the individual contributions of the two genes in tumor suppression (Serrano et al., 1996; Kamijo et al., 1997) . While analysis of both familial and sporadic cancerassociated mutations have indicated that INK4a, not ARF, is preferentially being targeted (Quelle et al., 1997) , mice lacking p19ARF but retaining intact p16INK4a develop multiple tumors (Kamijo et al., 1997) , indicating that ARF, like INK4a, is also a bona fide tumor suppressor. Unlike INK4a, which binds to and inhibits the activity of CDK4/6 (Serrano et al., 1993; Xiong et al., 1993a) , ARF does not induce cell cycle arrest by acting directly as a CDK inhibitor (Quelle et al., 1995) , and there is no evidence that ARF exerts its growth-inhibitory effect through the pRB pathway; instead, it requires the presence of wild-type p53 for induction of a G1 cell cycle arrest. Established cell lines that lack p53 or have p53 mutations are resistant to growth arrest by ectopic expression of ARF (Kamijo et al., 1997) , suggesting that ARF may act upstream of p53. We report here that hu- tumor suppression pathways.
(B) Epitope-tagged (HA or myc) human ARF and MDM2 were in vitro translated in the presence of [ 35 S]methionine, either separately (lanes 1-8, 11, 13-15, 18, and 19) or together (lanes 9, 10, 12, 16, 17, 20, Results and 21). IVT products either directly underwent SDS-PAGE (input, lanes 13-17) or were mixed to allow complex formation and then immunoprecipitated with the indicated antibodies prior to electro-
Human ARF Binds to MDM2
phoresis.
We used the yeast two-hybrid system to search for pro-(C) HeLa-tet off cells were cotransfected with vectors expressing teins capable of physically interacting with human ARF human mdm2 and either HA-tagged INK4a (HA-INK4a), HA-tagged (Fields and Song, 1989) . A 0.4 kb cDNA fragment encod-ARF (HA-ARF), or the parental pTRE vector. Two days after transfecing the 132 amino acid residues of full-length human ARF tion, cell lysates were prepared and immunoprecipitated with affinwas fused in-frame with the yeast Gal4 DNA-binding ity-purified antibodies to ARF (␣-ARF), to HA (␣-HA), or to HA antisera blocked with HA peptide (␣-HA ϩ HA). Immunoprecipitates domain (Gal4-BD). The resulting vector was cotrans- ( Figure 1A and data not shown). Direct DNA sequencing of the rescued plasmid revealed that this clone encodes a truncated human MDM2 containing the C-terminal 284 the growth of HF7c yeast cells in the presence of the amino acids (beginning with residue 208), suggesting histidine synthesis inhibitor 3-amino-1, 2, 3-triazole (3-that the ARF protein may interact with a C-terminal do-AT, data not shown). ARF was unable to interact with main of MDM2. The interaction between ARF and MDM2 the GAL4 DNA activation domain (negative control) expressed from the parental vector pGAD-GH. Conversely, protein appeared to be relatively strong as indicated by human INK4a fused with Gal4-BD was able to interact with CDK4 but not with MDM2 ( Figure 1A) .
We confirmed ARF-MDM2 binding in a cell-free system using in vitro translated proteins ( Figure 1B Figure 1B ) or ectopic expression in mammalian cells (see below), resolved by SDS-PAGE into two discrete bands. The exact nature and origin of these two forms of MDM2 protein have not been determined. No detectable differences were observed between these two forms throughout the study. Neither the myc nor the ARF antibody crossreacted with MDM2, and likewise the MDM2 antibody did not cross-react with ARF ( Figure 1B , lanes 1-6). MDM2 protein was coprecipitated with ARF by both the anti-ARF (lanes 7-10) and the anti-myc antibodies (lanes 11 and 12) whether ARF and MDM2 proteins were cotranslated (lanes 9, 10, and 12) or mixed after separate parental vector (pTRE). Expression of similar amounts of MDM2 protein in all the transfections was confirmed exon 1␤, which encodes 64 amino acids residues. The by immunoblotting of total cell lysates with anti-MDM2 exon 1␤ domain by itself can induce a G1 cell cycle antibody ( Figure 1C , lanes 1-3). Protein complexes were arrest with a potency similar to if not higher than that also examined by sequential immunoprecipitation and of full-length ARF, and deletion of exon 1␤ resulted in immunoblotting (IP-Western). When total cell lysates a mutant ARF that was unable to arrest the cell cycle were immunoprecipitated with an antibody specific to (Quelle et al., 1997) . To identify the domains within ARF either ARF or HA, MDM2 protein was detected in the that are required for binding to MDM2, we constructed lysate derived from cells cotransfected with MDM2 and two ARF mutants, one containing the N-terminal 64 ARF (lanes 10 and 11) but not in cells cotransfected with amino acids encoded by exon 1␤ and the other lacking MDM2 and either the parental pTRE vector (lanes 4-6) the exon 1␤ encoded N-terminal 64 amino acids, and or INK4a (lanes 7-9). Coprecipitation of MDM2 with HAtested their ability to bind MDM2. Because our anti-ARF was efficiently blocked by the preincubation of the ARF C-terminal peptide antibody does not recognize anti-HA antibody with a competing antigenic HA peptide the N-terminal domain, we added a myc epitope tag to (lane 12). Reciprocally, the ARF, but not the INK4a, prothe amino terminus of both mutants (myc-ARF[N] and tein was detected in anti-MDM2 immunoprecipitates demyc-ARF[C], respectively). In vitro translated, [ 35 S]-rived from cells cotransfected with MDM2 ( Figure 1D ). labeled wild-type or mutant ARF protein was mixed with similarly produced full-length MDM2 protein and reciprocally immunoprecipitated with antibodies to either ARF Interacts with MDM2 via an Exon 1␤-Encoded Domain MDM2 or the myc epitope (Figure 2 , top). We first confirmed the expected effects on the cell cycle by the The ARF and INK4a genes share common exons 2 and 3, but each contains a unique exon 1. Deletion analysis ectopic expression of each ARF construct. As previously observed, expression of the exon 1␤-encoded domain has mapped the cell cycle arrest activity of ARF within p53. Formation of a ternary ARF-MDM2-p53 complex suggests that if ARF regulates MDM2 function, it may not involve simple competitive disruption of MDM2's association with p53. Therefore, we examined the possibility that ARF affects the stability of MDM2. HeLa cells were transfected with plasmid vectors expressing MDM2 with or without ARF or mdm2 and p53 with and without ARF, and the half-life of MDM2 was determined by pulse-chase labeling ( Figure 4A ). Ectopically expressed MDM2 alone has a half-life of approximately 90 min in HeLa cells. Coexpression of MDM2 with ARF dramatically reduced the half-life of MDM2 protein to approximately 30 min regardless of the presence or absence of p53 ( Figure 4B ). To determine whether the ARFdependent shortened half-life of MDM2 decreased the steady-state level of MDM2 protein, total cell lysate derived from transfected HeLa cells was separated by MDM2 protein. The apparent constant steady-state level of p53 protein resulting from the transfections in this is sufficient to cause a G1 cell cycle arrest with similar experiment was by design. By transfecting with high potency to that caused by the full-length ARF (Figure 2 , levels of p53 expressing vector, we could determine bottom). While the C-terminal domain mutant did not whether the change in MDM2 protein abundance mediexhibit any detectable interaction with MDM2 (lanes 7 ated by ARF is p53 protein level independent. and 10), the N-terminal domain of ARF binds to MDM2
Of potential significance is a distinct mobility shift of with similar affinity as full-length ARF (compare lanes 5 the MDM2 protein upon coexpression with ARF protein and 6, 8 and 9), indicating that the N-terminal 64 amino ( Figure 3 , compare lanes 10 with 11 and 12; Figure 4A , acids encoded by exon 1␤ are both required and sufficompare lanes 1-6 with lanes 7-12; lanes 13-18 with cient for binding to MDM2.
lanes 19-24). We have not determined the nature of this ARF-promoted MDM2 modification and whether this ARF Forms a Ternary Complex modification regulates the stability of MDM2. with MDM2 and p53 MDM2 binds p53 through an N-terminal domain (Chen Degradation of MDM2 by ARF Leads to p53 et al., 1993; Oliner et al., 1993) . The observation that Stabilization and Accumulation ARF binds to a C-terminal domain of MDM2 prompted MDM2 promotes the rapid degradation of p53 (Haupt us to test whether ARF can form a ternary complex et al. , Kubbutat et al., 1997 . To test whether ARFwith MDM2 and p53. HeLa cells were transfected with promoted MDM2 degradation leads to p53 stabilization combinations of plasmid vectors expressing ARF, MDM2, and accumulation, we determined the half-life of p53 in and/or p53. Transfected cells were metabolically labeled cells cotransfected with either MDM2 or MDM2 plus ARF with [
35 S]methionine, and the cell lysates were immuno-( Figure 5A ). The half-life of p53 ectopically expressed precipitated with antibodies specific to each of the indiin HeLa cells is approximately 3 hr, shorter than the vidual proteins. All three antibodies specifically recogestimated 7 hr half-life determined in Saos-2 cells (Kubnized their target proteins (Figure 3, lanes 3, 10, and 14) butat et al., 1997). We presume this change in p53's halfand did not cross-react with the other two proteins life is due to an E6-activated p53-degradation activity (lanes 4, 9, and 17). Both binary ARF-MDM2 (lanes 5 present in HeLa cells. Ectopic expression of p53 apparand 11) and MDM2-p53 (lanes 10 and 16) complexes ently overides the E6-mediated p53 degradation activity, can be readily precipitated using antibodies to either as evidenced by the accumulation of p53 (see below). relevant protein. In cells triply transfected with plasmids This is consistent with previous observations that treatexpressing all three proteins, an ARF-MDM2-p53 terment of HPV-positive cells with genotoxic agents, such nary complex was formed as determined by the presas UV and mitomycin, resulted in an increase of p53 ence of ARF in anti-p53 immunoprecipitates (lane 18) protein and its transactivating activity (e.g., Butz et al., and reciprocally p53 in anti-ARF precipitates (lane 6). In 1995). Cotransfection of a p53 expressing plasmid with the absence of MDM2, ARF and p53 association was a plasmid expressing MDM2 reduced the half-life of p53 not detectable (lanes 3 and 15) , indicating that the ARFfrom 3 hr to about 60 min. Triple transfection of plasmids p53 association is bridged by MDM2. expressing p53, MDM2, and ARF completely restored the half-life of p53 to 3 hr ( Figure 5B ). To test whether ARF Promotes the Rapid Degradation of MDM2 inhibition of MDM2-promoted p53 destabilization by The main function of MDM2 is to regulate p53 by complexing with and promoting the rapid degradation of ARF results in p53 accumulation, the steady-state level suggesting the possibility that ARF like MDM2 may be regulated by proteolysis. It is interesting to note that restored p53 steady-state levels to a level similar to that seen in singly transfected cells (compare lanes 1 and unlike ARF, INK4a is a protein with a long half-life (with little change over a 3 hr half-life experiment) (Parry et 3), indicating that ARF blocks MDM2-promoted p53 degradation. We purposely used 5:5:1 ratio of ARF, al., 1995) , further underscoring the distinction between these two proteins. The half-life of ARF protein did not MDM2, and p53 expressing plasmids in this experiment to ensure that adequate levels of MDM2 and ARF would change significantly in the presence of either ectopically expressed MDM2 or MDM2 plus p53 (data not shown). be present to affect p53 levels. 
ARF Reverses MDM2's Abrogation of p53-Mediated Growth Arrest
Forced overexpression of MDM2 is able to completely abolish the G1 cell cycle arrest caused by p53 (Chen et al., 1994; 1996) . Given the effects of ARF expression on the stability of MDM2 and p53 proteins, we sought to determine if ARF could reverse MDM2's abrogation of p53-induced cell cycle arrest. The human U2OS cell line, a human osteosarcoma line that contains wild-type p53, was transfected with combinations of plasmids driving expression of p53, MDM2, and ARF. Cells were simultaneously transfected with the cell surface marker CD20 to allow selection of transfected cells. Following transfection, a portion of the cells was analyzed for cell cycle distribution by flow cytometric analysis of CD20-positive cells, while another portion was analyzed for the expression of individual proteins. Consistent with previous reports (Chen et al., 1996) , ectopically expressed p53 caused cell cycle arrest in G1, and this p53-mediated G1 arrest was overcome by MDM2 ( Figure 6A , 6B). When ARF was cotransfected into cells overexpressing p53 and MDM2, it restored the G1 arrest to the level seen in cells singularly transfected by p53. Analysis of protein expression by immunoblotting revealed that p53 transfection resulted in an increase in the steady-state level of endogenous p21 ( Figure 6C ). The increase in p21 is most likely due to transcriptional activation by p53, since cotransfection of MDM2 resulted in a decrease in p21 protein levels to that seen in cells transfected with vector alone. Ectopic expression of ARF in addition to p53 and MDM2 restored the p53-induced p21 protein levels and was associated with a decrease in the steady-state levels of the MDM2 protein similar to that observed in HeLa dation. The simplest explanation for the cancellation of MDM2-imposed abrogation of p53-mediated arrest by ARF is that the rapid degradation of MDM2 by ARF leads 1997), suggesting that ARF may act upstream of p53. to p53 stabilization and accumulation.
Here, we present evidence that the ARF protein can stabilize the p53 protein by binding to and promoting Discussion the degradation of MDM2, providing a molecular mechanism for ARF function in cell cycle control and tumor The ARF-INK4a locus encodes two unrelated proteins suppression. both capable of inducing cell cycle arrest when overexDestabilization of MDM2 by ARF precluded detection pressed (Serrano et al., 1993; Quelle et al., 1995) . The of in vivo complex formation between these two proINK4a protein inhibits cell cycle progression by binding teins. However, four different assays all indicate that to and inhibiting the activity of cyclin D-dependent kithis interaction is direct and not bridged by another nases 4 and 6 (CDK4 and CDK6), thereby maintaining molecule: the yeast two-hybrid assay, reconstitution in the pRB protein in its growth suppressive, hypophosinsect cells through baculovirus expression, an in vitro phorylated state. The ARF protein, when ectopically exbinding assay, and in vivo transfection of mammalian pressed, causes cell cycle arrest in cells containing wildtype p53 but not in p53-deficient cells (Kamijo et al., cells (see also Pomerantz et al., 1998 [ 
this issue of Cell]).
The binding domains for the ARF-MDM2 interaction activity). In the absence of E6, E6AP does not bind to p53 (Huibregtse et al., 1991; Scheffner et al., 1993) . On have been mapped to the N-terminal and C-terminal regions of ARF and MDM2, respectively. Ectopic expresthe other hand, MDM2 promotion of p53 degradation requires direct binding of MDM2 to p53 and is indepension of the exon 1␤-encoded N-terminal region of murine ARF has been previously shown to be both necessary dent of both E6 and E6AP (Haupt et al., 1997; Kubbutat et al., 1997) . This suggests that E6 and MDM2 utilize and sufficient to cause cell cycle arrest (Quelle et al., 1997) . Our finding that ARF binds MDM2 through exon different mechanisms to selectively target p53 for degradation and that ARF stabilizes p53 independently of 1␤-encoded sequences domain is entirely consistent with and further supports the biological activity of this E6. Third, if the increase in MDM2 degradation by ARF required or was enhanced by E6, it would suggest that domain in arresting the cell cycle. MDM2 binds to p53 via its N-terminal domain, and deletion of the C-terminal E6 itself is associated with an activity that promotes MDM2 degradation. In essence, that would lead to an portion has little effect on the binding of MDM2 to p53 (Chen et al., 1993; Oliner et al., 1993) , indicating that the E6-promoted p53 stabilization, rather than degradation as has been observed. Finally, transfection of U2OS highly conserved central and C-terminal regions may encode a separable function(s). The C-terminal 284 resicells, a human osteosarcoma cell line that does not contain E6, by p53 resulted in a cell cycle arrest that dues of MDM2 is sufficient to interact with ARF ( Figure  1A) , assigning a possible function to this ARF-binding was abrogated by cotransfection of p53 and MDM2. The p53-mediated arrest was restored by triple transfection region as important in regulation of MDM2 stability and abundance.
with p53, MDM2, and ARF ( Figure 6 ). In these transfected cells, ectopic expression of p53 resulted in an increase The functional significance of the ARF-MDM2 interaction is not fully understood at present. One consequence in p21, cotransfection of p53 with MDM2 reduced p21 to background level, and triple transfection with ARF of the ARF-MDM2 interaction is promotion of MDM2 protein degradation. The half-life of ectopically exrestores p21 back to the level seen in p53-singly transfected cells. Although we only determined the steadypressed MDM2 protein in HeLa cells of approximately 90 min was reduced to 30 min by cotransfection of an state level of each protein, not their half-lives, this result supports and is consistent with the finding made in HeLa equal amount of plasmid vector expressing ARF ( Figure  4A ). Reduction of the half-life of MDM2 by ARF is associcells that ARF promotes MDM2 degradation. Our results, however, do not exclude the possibility that ARF ated with a decrease in the steady-state level of MDM2 protein to nearly background level in transfected cells, may regulate MDM2 through other mechanisms in addition to promoting its degradation. Intriguingly, ARF, indicating the potency of ARF in promoting the degradation of MDM2. Consequently, the p53 protein, which is MDM2, and p53 can form a stable ternary complex, likely bridged by MDM2 via its two separate domains, which destabilized by overexpression of MDM2, is stabilized by the coexpression of ARF, restoring the p53 level to can independently interact with p53 and ARF (Figure 3) . It is conceivable that ARF may be able to ablate MDM2's that seen in singly transfected cells ( Figure 5C ). We further note that ARF itself is a short-lived protein with functional repression of p53-mediated transcription (Thut et al., 1997) . its estimated half-life being approximately 90 min in transfected HeLa cells, suggesting the possibility that Normally, p53 protein is kept at a low concentration in a cell by its relatively short half-life. Several types of the abundance of ARF may also be subjected to regulation at the level of protein stability. cellular stresses, particularly DNA damage, result in a rapid increase in p53 concentration. The mechanism by The biochemical mechanism underlying ARF-promoted MDM2 degradation, as in the case of MDM2-which these genotoxic stresses induces p53 accumulation is not well understood but likely involves lengthenpromoted p53 degradation, remains to be elucidated. Whether the degradation of MDM2, like that of p53 (Maki ing p53's half-life. The major function of MDM2 in vivo appears to be regulation of p53, as evidenced by the et al. 1996), is also mediated by an ubiquitin-dependent pathway is not known. ARF-promoted MDM2 degradarescue of embryonic lethality of mdm2-deficient mice by codeletion of p53 (Jones et al., 1995; Luna et al., tion could be indirect (e.g., by regulating the modification of MDM2 and p53) or direct (e.g., by acting as an 1995). The p53 protein is significantly destabilized by the overexpression of MDM2 (Haupt et al., 1997 ; Kubbutat et E3-like ubiquitin ligase to target MDM2, analogous to HPV E6-promoted p53 degradation). A possible complial., 1997) ( Figure 5A ), leading to the postulation that MDM2 may play a role in maintaining low levels of p53 cation stems from the presence in HeLa cells of HPV-16 E6 protein, which can utilize the cellular proteolytic in normal cells as well as in removing p53 during recovery from stress-induced arrest through a feedback regusystem to target p53 for ubiquitin-dependent degradation (Scheffner et al., 1990 (Scheffner et al., , 1993 . Although there is no latory loop. While it is tempting to speculate that ARF may be activated by stress to cause MDM2 degradation evidence that E6 could have a similar effect on the stability of MDM2, we cannot firmly exclude the possibility and p53 accumulation, it has been observed that induction of p53 and p21 by ␥ irradiation does not depend that E6 may have contributed to ARF-promoted MDM2 degradation through an as yet unknown mechanism.
on ARF (Kamijo et al., 1997) . This indicates that, at least in the case of DNA double-strand breaks produced by Several observations, however, argue against such a possibility. First, binding of ARF to MDM2 does not re-␥ irradiation, ARF plays at most a redundant, if not a minor, role in mediating p53 accumulation. Therefore, quire any other protein, and expression of E6 in HeLa cells does not disrupt this interaction. Second, E6 taras with INK4a, elucidating the cellular signals that regulate the level or activity of ARF remains a major chalgets p53 for degradation by promoting the interaction of p53 with E6AP (a protein containing ubiquitin ligase lenge.
Experimental Procedures
Plasmid Constructs Exon 1␤ of human ARF was amplified from human placental cDNA by polymerase chain reaction (PCR) using the following oligonucleotide primers based on published human ARF sequence (Duro et al., 1995; Mao et al., 1995; Stone et al., 1995) : E1S (sense) 5Ј-GGAATTCCCAT GGTGCGCAGGTTCTTGGTGACC-3Ј and E1A (antisense) 5Ј-CATCA TCATGACCTGGTCTTCTAGGAAGCGGCTGCT-3Ј. EcoRI and NcoI restriction sites were incorporated into the sense primer (underlined) to facilitate subsequent cloning. Exons 2 and 3 were PCR amplified from human INK4a cDNA using the following primers (Serrano et al., 1993) : E2S (sense) 5Ј-CTAGAAGACCAGGTCATGATGATGGGC AGC-3Ј and E2A (antisense) 5Ј-CGATGAATTAAGCTTGAGCTCGG-3Ј (a natural HindIII site present in the 3Ј UTR of ARF and INK4a is underlined). PCR conditions were: 1 M each oligonucleotide, 2 U Taq polymerase, and 1X PCR buffer (Perkin-Elmer, Roche). For amplification of exon 2-3, dimethylsulfoxide (DMSO) was added to a final concentration of 5%. Thirty cycles of amplification were completed using the following cycling temperatures: denaturation for 30 s at 95ЊC, annealing for 60 s at 55ЊC for exon 1␤ or 50ЊC for exon 2-3, and elongation for 90 s at 72ЊC. The amplified exon 1␤ and exon 2-3 were mixed in a 1:1 ratio and reamplified using sense E1S and antisense E2A primers under the same conditions as for exon 2 PCR except that the annealing temperature was 45ЊC. The PCR product containing full-length human ARF coding sequence Figure 7 . INK4a and ARF Pathways was first subcloned into a GST fusion expressing vector, pGEX-KG, (A) ARF, via an exon 1␤-encoded N-terminal domain, binds to a after restriction with NcoI and HindIII yielding pGEX-ARF, which C-terminal portion of MDM2 and promotes its degradation (indicated was verified by DNA sequencing. From pGEX-ARF, a series of ARF by stippled appearance). MDM2 via an N-terminal domain forms a derivative plasmids were constructed by subcloning into pCI-neo complex with and promotes the degradation of p53. ARF-promoted (Promega) and adding an amino terminal HA epitope-tag into the MDM2 degradation is also associated with ARF-dependent MDM2 NcoI EcoRI site of pCI-neo or by subcloning into pcDNA3-myc (a modification, but the significance of this modification in regulating modified pcDNA3 vector that contains a myc epitope tag downthe degradation of MDM2 is not clear. p53 is also a phosphoprotein, stream of a CMV and a T7 promoter, InVitrogen), to yield pCI-neoand phosphorylation of p53 by DNA-dependent protein kinase (DNA-HA-ARF and pcDNA3-myc-ARF that were used for both in vitro PK) following DNA damage hinders its interaction with MDM2 (Shieh translation using T7 RNA polymerase and expression in mammalian et al., 1997). The mdm2 gene itself is activated by p53, creating an cells from the CMV promoter. The HA-ARF fragment was further autoregulatory feedback loop (Barak et al., 1993 (Barak et al., , 1994 subcloned from pCI-neo-HA-ARF into the pTRE vector (Clontech, 1993) .
Palo Alto, CA) that contains a CMV promoter under the control of (B) Comparison of the ARF-MDM2-p53 pathway and the INK4a-a tetracyclin response element to yield pTRE-HA-ARF, which is cyclin D/CDK4,6-pRB pathway. The regulation of both ARF and suitable for expression in tetracyclin-inducible HeLa cells (HeLaINK4a is not known. tet off, Clontech). ARF deletion mutants were constructed by PCR using pcDNA3-myc-ARF as a template. The two pairs of primers used were as follows: 5Ј-TAATACGACTCACTATAGGG-3Ј (sense, a T7 primer) and 5Ј-TTACTCGAGTCATGGTCTTCTAGGAAGCGGCTG Our finding that ARF stabilizes p53 by promoting the CTG-3Ј (antisense, a XhoI site incorporated for subsequent subclondegradation of MDM2 reveals a tumor suppression pathing, is underlined) to generate a fragment corresponding to the way that involves two tumor suppressors, ARF and p53, N-terminal 64 amino acids encoded by exon 1␤; 5Ј-ATAGAATTCGG both of which are frequently inactivated in many types TCATGATGATGGGCAGCGC-3Ј (sense, an EcoRI site is underlined) of human cancers, and a proto-oncogene, mdm2, that and E2A (antisense) to generate a fragment corresponding to the C-terminal 68 residues lacking exon 1␤. Both PCR products is genomically amplified with high frequency in human were cloned into pcDNA3-myc to yield pcDNA3-myc-ARF(N) and sarcomas ( Figure 7A ). There is a striking similarity bepcDNA3-myc-ARF(C), respectively. All ARF plasmids were contween this pathway and another major tumor suppresfirmed by direct sequencing of isolated plasmids.
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